Loading
A phase 2 trial of Belzutifan, Fulvestrant, Everolimus and Exemestane in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) is a phase 2 interventional study registered as NCT06428396 by Merck Sharp & Dohme LLC, with 120 participants enrolled, started 2024-11-27 and due to reach its primary completion in 2027-05-05. Interventions recorded: Belzutifan, Fulvestrant, Everolimus and Exemestane.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/